Purpose: The aim of this work was to analyze and contrast the effectiveness and safety of
intralesional HA in the acute stage of PD with that of verapamil injection.
Methods: In this prospective, randomized clinical trial, 42 PD-affected, sexually active men
between the ages of >18 and 70 participated. Two groups of patients were recruited; group
A obtained weekly intralesional treatment with HA for 12 weeks, whereas group B obtained
weekly intralesional therapy with verapamil for 12 weeks. Physical examinations and Duplex
Doppler ultrasound were performed on all patients.
Results: The penile curvature was significantly decreased at 12 weeks after therapy in contrast
to baseline in group A (34.1 ± 6.77° vs. 24.7 ± 9.72°, p = 0.005), and was significantly decreased
at 12 weeks after therapy compared to baseline in group B (36.2 ± 7.43° vs. 30.8 ± 8.63 °, p =
0.047). The decrease in penile curvature at 12 weeks after therapy was noticeably better in
group A in contrast to group B (24.7 ± 9.72° vs. 30.8 ± 8.63°, p = 0.038).
Conclusion: HA is emerging as a valid choice for the treatment of PD in terms of resolution of
the acute phase of the disease, and it is plausible to posit that the use of HA may contribute to
the stabilization of the disease and decrease the need for the subsequent choice of a possible
surgical strategy, with the ability to reduce penile pain and have a stronger impact on penile
curvature and patient satisfaction.